Supported by

Tricuspid / Pulmonary valve

Latest tricuspid content in interventional cardiology - research, practice, and education

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

519 results

What’s new in the 2025 guidance on valvular heart disease - ESC Congress 2025

05 Sep 2025

In this interview, Alex Sticchi speaks with Fabien Praz and Michael Borger, co-chairs of the 2025 ESC/EACTS Valvular Guidelines Task Force. They discuss the major updates, including the central role of multimodality imaging, the lowered age threshold for TAVI, the distinction between atrial and ventricular secondary...

What’s new in the 2025 guidance on valvular heart disease - ESC Congress 2025

Key updates in valvular heart disease management: insights from the 2025 ESC/EACTS Guidelines

03 Sep 2025

Alex Sticchi provides his take on the new ESC Valvular Guidelines presented at the ESC Congress 2025 in Madrid.

Alessandro Sticchi

Author

Alessandro Sticchi
Key updates in valvular heart disease management: insights from the 2025 ESC/EACTS Guidelines

PCRonline @ ESC Congress 2025: the interventional cardiology perspective!

26 Jul 2025

Stay updated with the latest in interventional cardiology at #ESCCongress 2025!

PCRonline @ ESC Congress 2025

The PCR Textbook

08 Jul 2025

The PCR Textbook covers the length and breadth of percutaneous cardiovascular interventional practice, in particular diagnostic and therapeutic areas.

The PCR Textbook in percutaneous cardiovascular interventional practice

Transcatheter tricuspid valve interventions

01 Jul 2025

Several transcatheter tricuspid valve therapies are available to address different targets, including leaflet approximation, annuloplasty, valve replacement, valve-in-valve implantation and heterotopic valve implantation. Such devices and their initial promising evidences are reviewed in this up-to-date chapter!

Authors :

Nicola Buzzatti, Jean-Michel Juliard, Fabien Praz, Alec Vahanian, Azeem Latib, Eric Brochet, Phalla Ou, Dominique Himbert, Mirjam Wild, Domenico Angellotti
Transcatheter tricuspid valve interventions

Tricuspid Valve sessions from PCR London Valves 2025: Abbott

26 Nov 2025

Watch these recordings from PCR London Valves 2025 and EuroPCR 2025 on tricuspid valve.

Tricuspid session from PCR London Valves 2025: Abbott

Learn the latest from the PCR Tricuspid Focus Group!

Launch the video to hear Marianna Adamo and Marta Sitges share how they and Julien Dreyfus strengthened the Leadership team at the end of last year, bringing welcome support to founders Francesco Maisano and Fabien Praz.
 
They explain their individual roles among the PCR Tricuspid Focus Group;...

Learn the latest from the PCR Tricuspid Focus Group!

Repair and replace: latest insights in transcatheter treatment of mitral and tricuspid regurgitation

20 May 2025 – From EuroPCR 2025

Join Michael Mullen, Federico De Marco, and Philipp Lurz as they discuss the latest breakthroughs in the treatment of mitral and tricuspid regurgitation at EuroPCR 2025. In this roundtable session, they delve into both repair and replacement techniques, offering insights into new systems and their impact...

Repair and replace: latest insights in transcatheter treatment of mitral and tricuspid regurgitation

Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study

20 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).

The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...

Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study

Tricuspid regurgitation and heart failure with preserved ejection fraction

11 Jun 2025

Watch the replay of this webinar with M. Adamo, M. Metra, K-P. Kresoja, P. Lurz, P. Ponikowski and M. Sitges and learn about mechanisms and risk factors for HFpEF and TR, and so much more!

Tricuspid regurgitation and heart failure with preserved ejection fraction